Cancer metastasis accounts for a significant proportion of morbidity and mortality in patients.
Effective means of treating disseminated disease remains elusive. The purpose of this study�…

Tumor angiogenesis is a rate-limiting factor for tumor growth, and the endothelial cells of
tumor vessels display specific features that can be exploited for the selective delivery of�…

The endothelium represents a potentially critical target for gene therapy because of its
anatomical location and its importance in the viability in both normal and malignant tissues�…

Tumor-associated vasculature is a relatively accessible component of solid cancers that is
essential for tumor survival and growth, providing a vulnerable target for cancer gene�…

A major limitation of cancer gene therapy is the difficulty of delivering a therapeutic gene to
distant sites of metastatic disease. A promising strategy to address this difficulty is to use�…

Human and mouse proliferation-competent, bone marrow or peripheral circulation derived
endothelial progenitor-like cells (EPCs) were isolated, expanded and genetically�…

To test the hypothesis that genetically modified bone marrow-derived endothelial progenitor
cells (EPCs) can be effective carriers of therapeutic agents to tumor sites, we utilized our�…

By virtue of their location within blood vessels and their ability to express foreign genes,
endothelial cells are attractive vehicles for the delivery of therapeutic molecules in vivo. We�…

Background Systemic administration of non‐viral gene therapy provides better access to
tumors than local administration. Development of a promoter that restricts expression of�…

A long-pursued goal in cancer treatment is to deliver a therapy specifically to metastases. As
a result of the disseminated nature of the metastatic disease, carrying the therapeutic agent�…